KDM4A and neoplasm: For instance, a JMJD2 inhibitor, NCDM-32B, effectively decreased cell growth of basal breast cancer cell lines.66 With structure-based drug design, a novel JMJD2 inhibitor QC6352 was developed, which potently suppressed the proliferation, sphere formation, and in vivo tumor growth of TNBC, as well as PDX models of colon cancer.389 Moreover, QC6352 abrogated EGFR expression, thereby overcoming therapeutic resistance in breast cancer.393 Recently TACH101, a pan inhibitor of the JMJD2 subfamily was introduced.